

Drug Utilization Review Board Meeting			
June 16, 2011			
Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
New Drug Reviews			
Oral Contraceptive			
	Beyaz	NP/PA	NP/PA
Hyperammonemic			
	Carbaglu	P/PA	P/PA
Emergency Contraceptive			
	Ella	NP/PA	Remain NP/PA until full DURB review completed
Multiple Sclerosis			
	Gilenya	NP/PA	Remain NP/PA until full DURB review completed
Anticoagulant			
	Pradaxa	NP/PA	Remain NP/PA until full DURB review completed

### **Therapeutic Class Review**

#### Alpha-1 Proteinase Inhibitors

Prior Authorization for all agents, Aralast-NP, Glassia, Prolastin-C, and Zemaira. Decision on step therapy will be made after full DURB review completed.

### **Clinical Utilization Reviews**

#### Acetaminophen-Containing Combination Products

No action will be taken against Acetaminophen-Containing Combination Products with strengths higher than 325mg of acetaminophen per unit during the 3-year phase-out period by the Food and Drug Administration and to educate providers through banners for both Pharmacy Services and Physician Services programs.

#### Cough and Cold Products

No action will be taken at this time.